Pro: 'The usefulness of biomarkers in glomerular diseases'. The problem: Moving from syndrome to mechanism - Individual patient variability in disease presentation, course and response to therapy

Nephrology Dialysis Transplantation

Volumn 30, Issue 6, 2015, Pages 892-898

  Mariani, Laura H ^a,b   Kretzler, Matthias ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

Author keywords

molecular taxonomy; nephrotic syndrome; precision medicine; translational medicine

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER;

ACCURACY; ALLELE; BIOSTATISTICS; CLINICAL FEATURE; DATA COLLECTION METHOD; DRUG TARGETING; GENE EXPRESSION; GENETIC EPIGENESIS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BIOPSY; MORPHOMETRICS; NONHUMAN; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; URINALYSIS; VALIDATION STUDY; BLOOD; CLASSIFICATION; DISEASE COURSE; GENETIC ASSOCIATION; GENETICS; GLOMERULUS; KIDNEY DISEASES; KIDNEY FUNCTION TEST; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; SYNDROME;

BIOMARKERS; DISEASE PROGRESSION; GENETIC ASSOCIATION STUDIES; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY GLOMERULUS; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; SYNDROME;

EID: 84939642750     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv108     Document Type: Review

References (56)

1. U.S. Renal Data System, USRDS. Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
2. Hingorani SR, Weiss NS, Watkins SL. Predictors of peritonitis in children with nephrotic syndrome. Pediatr Nephrol 2002; 17: 678-682
3. Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 2012; 7: 513-520
4. Ordonez JD, Hiatt RA, Killebrew EJ et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993; 44: 638-642
5. Ruth EM, Landolt MA, Neuhaus TJ et al. Health-related quality of life and psychosocial adjustment in steroid-sensitive nephrotic syndrome. J Pediatr 2004; 145: 778-783
6. Cattran DC, Alexopoulos E, Heering P et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 2007; 72: 1429-1447
7. Cigni A, Faedda R, Atzeni MM et al. Hormonal strategies for fertility preservation in patients receiving cyclophosphamide to treat glomerulonephritis: a nonrandomized trial and review of the literature. Am J Kidney Dis 2008; 52: 887-896
8. Hahn D, Hodson EM, Willis NS et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2007: CD001533. doi: 10.1002/14651858.CD001533.pub5
9. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 2010; 62: 9-21
10. Kidney Disease: Improving Global OUtcomes (KDIGO) Glomeulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2012; 2 (Suppl. 2): 139-274
11. N.R. Council (ed). Toward Precision Medicine: Buildling a Knowledge Network for Biomedical Reserach for a New Taoxonomy of Disease. Washington, DC: National Academies Press, 2011, p. 128
12. Buettner R, Wolf J, Thomas RK. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 2013; 31: 1858-1865
13. Rampal R, Levine RL. Leveraging cancer genome information in hematologic malignancies. J Clin Oncol 2013; 31: 1885-1892
14. Hodgin JB, Nair V, Zhang H et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 2013; 62: 299-308
15. Berthier CC, Bethunaickan R, Gonzalez-Rivera T et al. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol 2012; 189: 988-1001
16. Sadowski CE, Lovric S, Ashraf S et al. A single-gene cause in 29.5% of Cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2014; pii: ASN.2014050489 [Epub ahead of print]
17. Stanescu HC, Arcos-Burgos M, Medlar A et al. Risk HLA-DQA1 and PLA (2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364: 616-626
18. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845
19. Parsa A, Kao WH, Xie D et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183-2196
20. Kottgen A, Glazer NL, Dehghan A et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009; 41: 712-717
21. Martini S, Nair V, Keller BJ et al. Integrative biology identifies shared transcriptional networks in CKD. J Am Soc Nephrol 2014; 25: 2559-2572
22. O'Seaghdha CM, Yang Q, Wu H et al. Performance of a genetic risk score for CKD stage 3 in the general population. Am J Kidney Dis 2012; 59: 19-24
23. Loupy A, Lefaucheur C, Vernerey D et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol 2014; 25: 2267-2277
24. Wickman L, Afshinnia F, Wang SQ et al. Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases. J Am Soc Nephrol 2013; 24: 2081-2095
25. Troyanov S, Wall CA, Miller JA et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005; 16: 1061-1068
26. Gansevoort RT, Matsushita K, van der Velde M et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80: 93-104
27. Beck LH, Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21
28. Hoxha E, Kneissler U, Stege G et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012; 82: 797-804
29. Dahnrich C, Komorowski L, Probst C et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clinica Chimica Acta; Int J Clin Chem 2013; 421: 213-218
30. Zhou GY. Membranous glomerulonephritis associated with myeloperoxidase anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 2012; 32: 548-551
31. Du Y, Li J, He F et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PLoS ONE 2014; 9: e104936
32. US Food and Drug Administration. Anti-Phospholipase A2 Receptor - FDA. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K132195 (9 November 2014, date last accessed)
33. Bech AP, Hofstra JM, Brenchley PE et al. Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2014; 9: 1386-1392
34. Rovin BH, Song H, Birmingham DJ et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005; 16: 467-473
35. Fukagawa M, Noda M, Shimizu T et al. Chronic progressive interstitial fibrosis in renal disease - are there novel pharmacological approaches? Nephrol Dial Transplant 1999; 14: 2793-2795
36. Bohle A, Muller GA, Wehrmann M et al. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int Suppl 1996; 54: S2-S9
37. D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med 2011; 365: 2398-2411
38. Working Group of the International IgA Nephropathy Network and the Renal Pathology SocietyCattran DC, Coppo R et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545
39. Working Group of the International IgA Nephropathy Network and the Renal Pathology SocietyRoberts IS, Cook HT et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556
40. Walsh M, Sar A, Lee D et al. Histopathologic features aid in predicting risk for progression of IgA nephropathy. Clin J Am Soc Nephrol 2010; 5: 425-430
41. Lemley KV, Lafayette RA, Safai M et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61: 1475-1485
42. Barisoni L, Nast CC, Jennette JC et al. Digital pathology evaluation in the multicenter Nephrotic Syndrome Study Network (NEPTUNE). Clin J Am Soc Nephrol 2013; 8: 1449-1459
43. Lash JP, Go AS, Appel LJ et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009; 4: 1302-1311
44. Furth SL, Cole SR, Moxey-Mims M et al. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 2006; 1: 1006-1015
45. Levin A, Rigatto C, Brendan B et al. Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT). BMC Nephrol 2013; 14: 121
46. Junyent M, Martinez M, Borras M et al. Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. BMC Nephrol 2010; 11: 14
47. Stengel B, Combe C, Jacquelinet C et al. The French chronic kidney disease-renal epidemiology and information network (CKD-REIN) cohort study. Nephrol Dial Transplant 2014; 29: 1500-1507
48. Kronenberg F, Kuen E, Ritz E et al. Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol 2002; 13: 461-469
49. Gadegbeku CA, Gipson DS, Holzman LB et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 2013; 83: 749-756
50. Buyse M, Sargent DJ, Grothey A et al. Biomarkers and surrogate end points - the challenge of statistical validation. Nat Rev Clin Oncol 2010; 7: 309-317
51. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-935
52. Fassett RG, Venuthurupalli SK, Gobe GC et al. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80: 806-821
53. Hosmer DW, Taber S, Lemeshow S. The importance of assessing the fit of logistic regression models: a case study. Am J Public Health 1991; 81: 1630-1635
54. Leening MJ, Steyerberg EW, Van Calster B et al. Net reclassification improvement and integrated discrimination improvement require calibrated models: relevance from a marker and model perspective. Stat Med 2014; 33: 3415-3418
55. Leening MJ, Vedder MM, Witteman JC et al. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. Ann Intern Med 2014; 160: 122-131
56. Parikh CR, Coca SG, Thiessen-Philbrook H et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol 2011; 22: 1748-1757